Loading
A phase 1/2 trial of IMC-R117C in advanced solid tumours, run by Immunocore Ltd, now recruiting.
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers is a phase 1/2 interventional study registered as NCT06840119 by Immunocore Ltd, with 600 participants planned, started 2024-01-10 and due to reach its primary completion in 2026-11-30. Interventions recorded: IMC-R117C, Chemotherapy drug, Kinase inhibitor, Antiangiogenic Agent and Monoclonal antibody.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Immunocore, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/